Ball has started rolling
73% GM and this business will add 200 crs at the top line…and EBIT accretive…
PI may attain 8000cr topline this FY…and also the presentation, data is full of disclosures… 60% improvement in cash flow !!
Posts in category Value Pickr
Fdc ltd (10-08-2023)
Buyback Announcement: @Rs 500 worth 150 Cr (CMP: ~390ish / MCap: ~6500)
Link: https://www.bseindia.com/xml-data/corpfiling/AttachLive/ae13aebc-63a1-45c9-a652-fa2403c70cf5.pdf
Disc: Invested (Portfolio sizing HERE)
Natco Pharma: Focusing On Complex Products (10-08-2023)
Natco pharma results
Disc: invested
Force Motors – racing ahead! (10-08-2023)
Good set of quarterly numbers by Force Motors.
All time high EBIDTA margins.
PI Industries – Superior Business Model (10-08-2023)
Presentation and announcement
https://www.bseindia.com/xml-data/corpfiling/AttachLive/2f482e3e-f6d3-4bf2-ad8d-6f33302eff0c.pdf
Great results.
Granules India Ltd (10-08-2023)
From investor concall…loss of revenue estimate of Rs.150 Cr and failure to supply penalties of Rs.21 Cr …these are kind of one off …
R&D Exp of Rs.43 Cr in Q1FY24…expected to go upwards of Rs.50 Cr in subsequent quarters of FY24
Gradual improvement expected in Margin from Q2 onwards but management declined to confirm any guidance around revenue & margin for rest of FY24…
They also discontinued giving molecule wise sales break-up because of competition
Granules India Ltd (10-08-2023)
From investor concall…loss of revenue estimate of Rs.150 Cr and failure to supply penalties of Rs.21 Cr …these are kind of one off …
R&D Exp of Rs.43 Cr in Q1FY24…expected to go upwards of Rs.50 Cr in subsequent quarters of FY24
Gradual improvement expected in Margin from Q2 onwards but management declined to confirm any guidance around revenue & margin for rest of FY24…
They also discontinued giving molecule wise sales break-up because of competition
Granules India Ltd (10-08-2023)
From investor concall…loss of revenue estimate of Rs.150 Cr and failure to supply penalties of Rs.21 Cr …these are kind of one off …
R&D Exp of Rs.43 Cr in Q1FY24…expected to go upwards of Rs.50 Cr in subsequent quarters of FY24
Gradual improvement expected in Margin from Q2 onwards but management declined to confirm any guidance around revenue & margin for rest of FY24…
They also discontinued giving molecule wise sales break-up because of competition
Granules India Ltd (10-08-2023)
Q1FY24 results are out and as expected degrowth in revenue but substantial erosion in margins (due to loss of revenue while expenses incurred). While this could be one off but investor presentation doesn’t talk about what is revenue and profit guidance for rest of period unless I am missing something.